• Home
  • » 
  • Reports
  • » 
  • Aseptic Fill Finish Market by Type of Mo...

Aseptic Fill Finish Market

Aseptic Fill Finish Market by Type of Molecule, Type of Packaging Container Offered, Type of Drug Product, Scale of Operation, Company Size, Target Therapeutic Area and Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    March 2023

  • Pages
    390

  • View Count
    1463

  • Buy Now

Example Insights

Aseptic-Fill-Finish-Services-Market-Context-thumb Aseptic-Fill-Finish-Services-Market-List-of-Biologics-Fill-thumb Aseptic-Fill-Finish-Services-Market-Type-of-Drug-Products-offered-thumb
Aseptic-Fill-Finish-Services-Market-List-of-Small-Molecules-Fill-thumb Aseptic-Fill-Finish-Services-Market-Scale-of-Operation-thumb Aseptic-Fill-Finish-Services-Market-Partnerships-and-Collaborations-thumb
Aseptic-Fill-Finish-Services-Market-Distribution-by-Type-of-Molecule-thumb Aseptic-Fill-Finish-Services-Market-Distribution-by-Company-Size-thumb  

Report Description

Aseptic fill finish refers to accurate and sterile filling / sealing of drug products into packaging containers, such as vials, syringes, ampoules and cartridges. These aseptic conditions during fill finish operations are not only essential for ensuring end-user’s safety, but also maintaining pharmacological efficacy and product quality. It is worth noting that aseptic fill finish operations require skilled personnel, specialized automated equipment, cleanroom setup and continuous supervision to maintain the sterility and safety of the final drug product. However, given the high cost of specialized equipment and affiliated expertise required for such operations, it is difficult for a drug developer with limited finances and capacity constraints to meet the needs of their clientele. As a result, various stakeholders are outsourcing their fill finish related needs to contract service providers, in order to ensure the development of quality drug products. In fact, a number of companies are involved in offering biologics fill finish services and small molecule fill finish services. Additionally, there is a need for expanding the capacity to meet the anticipated demand for such operations. For this purpose, service providers have inked several agreements over the last few years. Driven by the consistent initiatives being undertaken by players in this domain, the aseptic fill finish services market is anticipated to grow at a steady pace, over the coming years.

Key Market Insights

The Aseptic Fill Finish Services Market by Type of Molecule (Small Molecules and Biologics), Type of Packaging Container Offered (Ampoules, Cartridges, Syringes and Vials), Type of Drug Product (Antibodies, Cell Therapies, Gene Therapies, Oligonucleotides, Recombinant Proteins, Vaccines and  Other Products), Scale of Operation (Preclinical / Clinical and Commercial), Company Size (Large, Mid-sized and Small), Target Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Infectious Diseases Oncological Disorders, and Other Disorders) and Geographical Regions (North America, Europe, Asia Pacific, Middle East and North Africa and Latin America): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and future opportunity for the aseptic fill finish service providers. The report answers many key questions related to this domain.

Growing Demand for Aseptic Fill Finish Services
Aseptic fill finish is a critical step in the production of drugs, as it involves the aseptic filling and packaging of therapeutic products into containers. In fact, even a minute error during the aseptic filling process can lead to microbial contamination, posing a considerable risk to the patient’s health. Therefore, aseptic fill finish operations need to be performed under controlled environmental conditions, in order to minimize the exposure of drug product to factors that could negatively impact its stability and efficacy. This, in turn, helps in extending the shelf life of a drug product. It is also worth mentioning that, in recent years, many players are carrying out fill finish operations using automated equipment, without any manual intervention. This practice is believed to enhance the production efficiency, minimize downtime, reduce waste production, as well as increase the overall productivity. ,  

Need for Outsourcing Aseptic Fill Finish Operations 
The growing demand for pharmaceutical and biopharmaceutical drug products has created a need for higher capacity for production of therapies and their corresponding aseptic fill finish operations. However, extensive capital investment and complex infrastructure is necessary for carrying out in-house filling of biologics and small molecules. In addition, mishandling of drug product during the fill finish process can lead to microbial contamination, which can subsequently result in the loss of drug product, production delays and most importantly, pose a risk to the patient’s health. These aforementioned challenges have prompted pharmaceutical drug developers to outsource their fill finish operations to service providers, which have the required aseptic facilities and specialized equipment to ensure the quality of end products. 
 
Key Drivers of the Aseptic Fill Finish Services Market
At present, the rising demand for outsourcing of aseptic fill finish services is driven by multiple factors, such as growing pipeline of drug products, stringent regulatory requirements, in-house capacity constraints, technological advancements and increased awareness related to the benefits of aseptic fill finish services. 

Current Market Landscape of Aseptic Fill finish Service Providers
The current market landscape features the presence of over 235 aseptic fill finish service providers, spread across the globe. Overall, the market seems to be well-fragmented, featuring the presence of large, mid-sized and small companies, which have the required expertise to offer aseptic fill finish services across different types of packaging containers. Additionally, various recent developments in this segment of the pharmaceutical industry indicate that service providers are actively upgrading their sterile pharmaceutical manufacturing capabilities and infrastructure to accommodate the current and anticipated demand for aseptic fill finish services.

Overall Size of the Aseptic Fill Finish Services Market
Driven by the growing pipeline of pharmaceutical and biopharmaceutical drug products, as well as the rising demand for contract services in this sector, the aseptic fill finish market is anticipated to grow at a compound annual growth rate (CAGR) of 7%, during the period 2023-2035. Specifically, in terms of type of packaging container, the highest share of the market is anticipated to be captured by vials and prefilled syringes. In addition, at present, a major proportion of the market is represented by players based in North America and Europe.

Key Players in the Aseptic Fill Finish Services Market
Examples of key players engaged in offering aseptic fill finish services for biologics and small molecules include (which have been captured in this report) Aenova, AbbVie Contract Manufacturing, APL, Asymchem, BioPharma Solutions, BioReliance, Boehringer Ingelheim BioXcellence, Catalent Biologics, Charles River Laboratories, CordenPharma, Delpharm, Fareva, Fresenius Kabi, Glaxo SmithKline, Hetero Drugs, Intas Pharmaceuticals, Lonza, Pierre Fabre, Patheon, Pfizer CentreOne, Plastikon Healthcare, PiSA Farmaceutica, Recipharm, Sharp Services, Wacker Biotech, Syngene, Takara Bio, WuXi Biologics, Siegfried and Wockhardt.

Scope of the Report

The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments, as defined in the below table:

Key Report Attributes Details

Forecast Period
  • 2023 – 2035

Type of Molecules
  • Small Molecules
  • Biologics

Type of Packaging Containers
  • Vials
  • Syringes
  • Ampoules
  • Cartridges

Type of Drug Products
  • Vaccines
  • Recombinantn Proteins
  • Antibodies
  • Oligonucleotides
  • Gene Therapies
  • Cell Therapies
  • Other Products

Target Therapeutic Area
  • Autoimmune Disorders
  • Cardiovascular Disorder
  • Infectious Disorders
  • Oncological Disorders
  • Other Disorders

Scale of Operation
  • Preclinical / Clinical
  • Commercial

Company Size
  • Large
  • Mid-sized
  • Small
Geography
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and North Africa
  • Latin America
Key Companies Profiled
  • AbbVie Contract Manufacturing
  • Asymchem 
  • Aenova 
  • APL 
  • BioPharma Solutions 
  • BioReliance 
  • Boehringer Ingelheim BioXcellence
  • Catalent Biologics
  • Charles River Laboratories 
  • CordenPharma 
  • Delpharm 
  • Fareva
  • Fresenius Kabi 
  • Glaxo SmithKline
  • Hetero Drugs 
  • Intas Pharmaceuticals 
  • Lonza 
  • Pierre Fabre 
  • Pfizer CentreOne 
  • Plastikon Healthcare 
  • Patheon
  • PiSA Farmaceutica 
  • Recipharm 
  • Wacker Biotech 
  • Syngene 
  • Sharp Services
  • Siegfried 
  • Takara Bio 
  • WuXi Biologics 
  • Wockhardt

(Full list of 235+ companies captured in the market landscape analysis of the report) 

Customization Scope
  • 15% Free Customization Option (equivalent to 5 analysts working days)

PowerPoint Presentation (Complimentary)
  • Available

Excel Data Packs (Complimentary)
  • Market Landscape Analysis
  • Developer Landscape Analysis
  • Partnerships and Collaboration Analysis
  • Market Forecast and Opportunity Analysis

The study also presents an in-depth analysis of various stakeholders engaged in this domain, highlighting their capabilities across different geographies. Following are some of the key focus areas and topics elaborated in this report:

  • A summary of the key insights derived from our research, which offers a high-level view on the likely evolution of the aseptic fill finish service providers market in the short to mid-term, and long term.
  • A general introduction to pharmaceuticals and contract manufacturing, which features a detailed discussion on the need for outsourcing within the pharmaceutical industry and key operations outsourced by biologic and small molecule drug developers, including fill finish. It also provides information on the key considerations for selecting a fill finish service provider, along with the advantages and risks posed by outsourcing fill finish operations.
  • A detailed assessment of the overall landscape of aseptic fill finish service providers, along with information on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of molecule(s) (biologics and small molecules) and type of packaging container(s) offered (ready-to-use cartridges, ready-to-use syringes and  ready-to-use vials).
  • A review of the overall landscape of companies offering aseptic fill finish services for biologics, along with analyses on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of fill finish facilities, type of packaging container(s) used (ampoules, cartridges, syringes and vials),  type of biologic(s) manufactured (antibody drug conjugates, antibodies, biosimilars, cell therapies, gene therapies, oligonucleotides, peptides / proteins, vaccines, viral products, and others), scale of operation (preclinical, clinical and commercial) and type of additional drug product-related service(s) offered (lyophilization, labeling, quality testing, storage and distribution services).
  • A detailed assessment of the overall market landscape of the companies offering aseptic fill finish services for small molecules, along with analyses on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of fill finish facilities, type of filling service(s) offered (aseptic filling, terminal streilization and blow-filling-seal), type of finishing service(s) offered (inspection and labelling and packaging), type of packaging container(s) offered (ampoules, cartridges, syringes and vials),  scale of operation (preclinical, clinical and commercial), type of dosage form(s) filled (solid, liquids, lyophilized products / powders and semi-solids), type of process(es) (automated and manual / semi-automated).
  • Tabulated profiles of key players based in North America, Europe and Asia-Pacific. Each profile provides an overview of the company, along with information on its service portfolio, fill finish facilities, financial information (if available), recent developments and an informed future outlook. 
  • A detailed analysis of the various partnerships and collaborations established by stakeholders in this domain, since 2013. It includes a brief description of different agreement models (including service agreements, service alliances, product integration agreements, joint ventures and acquisitions) adopted by stakeholders in this domain. Further, it comprises of analysis based on year of partnership, type of partnership, scale of operation, type of molecule(s), type of service(s) offered, type of process(es) involved, and type of drug product(s) filled. It also highlights the most active players (in terms of number of partnerships) in the domain.  
  • A case study focused on use of robotic systems in fill finish operations. It provides a list of equipment used by fill finish service providers (wherever specified), highlighting the purpose of robotics in various manufacturing operations. It also includes a list of companies offering robots for use in the manufacturing processes which are carried in the pharmaceutical sector.
  • A case study on use of ready-to-use packaging components in aseptic fill finish operations. The chapter also provides information related to the advantages and disadvantages of ready-to-use packaging components, along with a list of suppliers providing these components.

One of the key objectives of this report was to estimate the current market size and future opportunities in the aseptic fill finish services market, over the coming 12 years. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2023-2035. In order to provide a detailed future outlook, year-wise projections of the current and future opportunity have been further segmented on the basis of type of molecule (small molecules and biologics), type of packaging container offered (ampoules, cartridges, syringes and vials), type of drug product (antibodies, cell therapies, gene therapies, oligonucleotides, recombinant proteins, vaccines and  other drug products), target therapeutic area (autoimmune disorders, oncological disorders, cardiovascular disorders, infectious diseases and other disorders), scale of operation (preclinical / clinical and commercial), company size (large, mid-sized and small) and geography, (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America). To account for uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this report are backed by our understanding of key data generated from both secondary and primary research. The perceptions presented in this study were also influenced by our discussions with senior stakeholders in the industry. The report further features detailed transcripts of interviews held with the following industry and non-industry players:

  • Gregor Kawaletz (Former Chief Commercial Officer, IDT Biologika)
  • Matt Delaney (Former Vice President Business Development & Marketing, ‎Cytovance Biologics)
  • Purushottam Singnurkar (Vice President and Head of Formulation Development, Syngene International)
  • Ales Sima (Head of Business Development, Oncomed Manufacturing) 
  • Amit Chandra (Former Technology Watch Manager, Yposkesi)
  • Jos Vergeest (International Business Developer, HALIX)

All actual figures have been sourced and analyzed from publicly available forums and primary research discussions. It is important to highlight that, financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is the aseptic fill  finish?
Answer: Fill finish is the last step in the aseptic manufacturing process, where drug products are filled and packaged in various packaging containers, such as vials, syringes, ampoules and cartridges, under sterile conditions. Further, the process is carried out in a controlled cleanroom environment, which has low levels of particulate matter and microorganisms to prevent microbial contamination. It is worth mentioning that fill finish is a complex and highly regulated process, to ensure the safety and efficacy of these drug products, as any contamination could lead to serious health risks for patients. 

Question 2: What are the requirements and considerations for aseptic fill finish operation?
Answer: Aseptic filling process requires close coordination and complex interactions between supporting personnel and key operational equipment, sterilized drug product, cleanroom and other supporting facilities, and ancillary materials. 

Question 3: How many players are providing aseptic fill finish services?
Answer: Presently, more than 235 companies offer aseptic fill finish and other related services (such as aseptic filling, terminal sterilization and blow-fill-seal).

Question 4: What are the latest trends in aseptic fill finish services market?
Answer: Aseptic fill finish market is evolving to meet the growing demands of the pharmaceutical and biopharmaceutical industry. Advanced technologies, such as robotics and single-use systems are being adopted to improve the accuracy, efficiency and safety of aseptic fill finish procedures. In fact, single-use technology reduces the risk of cross-contamination and need for cleaning validation. Further, automated aseptic filling systems reduce the human interference and can meet various operational requirements, from loading of raw material to cleaning of the equipment. This, in turn, can improve the consistency and quality of the final product. 

Question 5: What is the growth rate of aseptic fill finish services market?
Answer: The global aseptic fill finish services market is expected to grow at a CAGR of 7%, during the period 2023-2035.

Question 6: Which region captures the largest share of the aseptic fill finish services market?
Answer: Currently, Europe contributes to more than 35% share of the overall market. Further, Asia-Pacific is likely to grow at a relatively faster pace, during the forecast period.

Question 7: Which segment, in terms of type of molecule, currently accounts for the largest share of the aseptic fill finish services market?
Answer: The small molecules segment currently holds the largest share (68%) in the overall aseptic fill finish services market. This trend is unlikely to change during the forecast period. 

Question 8: Which types of packaging containers are most widely used in the aseptic fill finish services market? 
Answer: Presently, the vials (67%) account for the largest share in the global aseptic fill finish services market. 

Question 9: What type of partnerships are taking place in the aseptic fill finish services market? 
Answer: At present, service agreements represent the most preferred type of partnership model adopted by stakeholders in this domain. This is followed by acquisitions and service alliances.

Contents

Table Of Contents

1. PREFACE
1.1. Chapter Overview
1.2. Key Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Contract Manufacturing  
3.3. Commonly Outsourced Operations in Biopharmaceutical Industry
3.3.1. Aseptic Fill / Finish Operations
3.4. Basic Guidelines for Selecting a Fill / Finish Service Provider
3.5. Advantages of Outsourcing Fill / Finish Operations
3.6. Risks and Challenges Associated with Outsourcing Fill / Finish Operations
3.7. Concluding Remarks
 
4. ASEPTIC FILL / FINISH SERVICE PROVIDERS LANDSCAPE
4.1. Chapter Overview
4.2. Aseptic Fill / Finish: Service Providers Landscape
4.2.1.  Analysis by Year of Establishment
4.2.2.  Analysis by Company Size 
4.2.3.  Analysis by Location of Headquarters  
4.2.4.  Analysis by Type of Molecule(s)
4.2.5.  Analysis by Type of Packaging Container(s) Offered
 
5. BIOLOGICS FILL / FINISH SERVICE PROVIDERS LANDSCAPE
5.1.  Chapter Overview  
5.2.  Biologics Fill / Finish: Service Providers Landscape
5.2.1.  Analysis by Year of Establishment  
5.2.2.  Analysis by Company Size 
5.2.3.  Analysis by Location of Headquarters  
5.2.4.  Analysis by Location of Fill / Finish Facilities  
5.2.5.  Analysis by Type of Packaging Container(s) Offered
5.2.6.  Analysis by Type of Drug Product(s) Involved
5.2.7.  Analysis by Scale of Operation
5.2.8.  Analysis by Additional Drug Product-related Services Offered
5.2.9. Information on Fill / Finish Capacity 
 
6. SMALL MOLECULE FILL / FINISH SERVICE PROVIDERS LANDSCAPE
6.1. Chapter Overview
6.2.  Small Molecule Fill / Finish: Service Providers Landscape
6.2.1.  Analysis by Year of Establishment
6.2.2.  Analysis by Company Size  
6.2.3.  Analysis by Location of Headquarters  
6.2.4.  Analysis by Location of Fill / Finish Facilities
6.2.5.  Analysis by Type of Filling Service(s) Offered
6.2.6.  Analysis by Type of Finishing Service(s) Offered
6.2.7.  Analysis by Type of Packaging Container(s) Offered
6.2.8. Analysis by Scale of Operation
6.2.9. Analysis by Type of Dosage Form(s) Filled
6.2.10. Analysis by Type of Process(es)
6.2.11. Information on Fill / Finish Capacity 
 
7. COMPANY PROFILES: ASEPTIC FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA
7.1. Chapter Overview
7.2. Companies Offering Aseptic Fill / Finish Services for Biologics
7.2.1. AbbVie Contract Manufacturing
7.2.1.1. Company Snapshot 
7.2.1.2. Financial Information
7.2.1.3. Service Portfolio
7.2.1.4. Fill / Finish Services Offered
7.2.1.5. Recent Developments and Future Outlook
 
7.2.2. BioPharma Solutions
7.2.2.1. Company Snapshot 
7.2.2.2. Financial Information
7.2.2.3. Service Portfolio 
7.2.2.4. Fill / Finish Services Offered 
7.2.2.5. Recent Developments and Future Outlook
 
7.2.3. BioReliance
7.2.3.1. Company Snapshot 
7.2.3.2. Financial Information
7.2.3.3. Service Portfolio 
7.2.3.4. Fill / Finish Services Offered 
7.2.3.5. Recent Developments and Future Outlook
 
7.2.4. Catalent Biologics
7.2.4.1. Company Snapshot 
7.2.4.2. Financial Information
7.2.4.3. Service Portfolio 
7.2.4.4. Fill / Finish Services Offered 
7.2.4.5. Recent Developments and Future Outlook
 
7.2.5. Charles River Laboratories
7.2.5.1. Company Snapshot 
7.2.5.2. Financial Information 
7.2.5.3. Fill / Finish Services Offered 
7.2.5.4. Recent Developments and Future Outlook
 
7.2.6. Patheon
7.2.6.1. Company Snapshot 
7.2.6.2. Financial Information
7.2.6.3. Service Portfolio 
7.2.6.4. Fill / Finish Services Offered 
7.2.6.5. Recent Developments and Future Outlook
 
7.3. Companies Offering Aseptic Fill / Finish Services for Small Molecules
7.3.1.1. Pfizer CentreOne
7.3.1.2. Company Snapshot
7.3.1.3. Service Portfolio
7.3.1.4. Fill / Finish Services Offered
7.3.1.5. Recent Developments and Future Outlook
 
7.3.2. Plastikon Healthcare 
7.3.2.1. Company Snapshot
7.3.2.2. Service Portfolio
7.3.2.3. Fill / Finish Services Offered
7.3.2.4. Recent Developments and Future Outlook
 
7.3.3. Sharp Services
7.3.3.1. Company Snapshot
7.3.3.2. Service Portfolio
7.3.3.3. Fill / Finish Services Offered
7.3.3.4. Recent Developments and Future Outlook
 
8. COMPANY PROFILES: ASEPTIC FILL / FINISH SERVICE PROVIDERS IN EUROPE
8.1. Company Overview
8.2. Companies Offering Aseptic Fill / Finish Services for Biologics
8.2.1. Boehringer Ingelheim BioXcellence
8.2.1.1.  Company Snapshot 
8.2.1.2. Financial Information
8.2.1.3. Service Portfolio
8.2.1.4. Fill / Finish Services Offered 
8.2.1.5.  Recent Developments and Future Outlook
 
8.2.2. Fareva
8.2.2.1. Company Snapshot 
8.2.2.2. Fill / Finish Services Offered
8.2.2.3. Recent Developments and Future Outlook
 
8.2.3. GlaxoSmithKline
8.2.3.1. Company Snapshot 
8.2.3.2. Financial Information
8.2.3.3. Fill / Finish Services Offered 
8.2.3.4. Recent Developments and Future Outlook
 
8.2.4. Lonza
8.2.4.1. Company Snapshot 
8.2.4.2. Financial Information
8.2.4.3. Service Portfolio 
8.2.4.4. Fill / Finish Services Offered 
8.2.4.5. Recent Developments and Future Outlook
 
8.2.5. Pierre Fabre
8.2.5.1. Company Snapshot 
8.2.5.2. Financial Information
8.2.5.3. Service Portfolio 
8.2.5.4. Fill / Finish Services Offered 
8.2.5.5. Recent Developments and Future Outlook
 
8.2.6.  Wacker Biotech 
8.2.6.1. Company Snapshot 
8.2.6.2. Financial Information
8.2.6.3. Service Portfolio 
8.2.6. 4. Fill / Finish Services Offered 
8.2.6.5. Recent Developments and Future Outlook
 
8.3. Companies Offering Aseptic Fill / Finish Services for Small Molecules
8.3.1. Aenova 
8.3.1.1. Company Snapshot 
8.3.1.2. Financial Information
8.3.1.3. Service Portfolio 
8.3.1.4. Fill / Finish Services Offered 
8.3.1.5. Recent Developments and Future Outlook
 
8.3.2. APL
8.3.2.1. Company Snapshot
8.3.2.2. Service Portfolio
8.3.2.3. Fill / Finish Services Offered
8.3.2.4. Recent Developments and Future Outlook
 
8.3.3 CordenPharma
8.3.3.1. Company Snapshot
8.3.3.2. Service Portfolio
8.3.3.3. Fill / Finish Services Offered
8.3.3.4. Recent Developments and Future Outlook
 
8.3.4. Delpharm
8.3.4.1. Company Snapshot
8.3.4.2. Service Portfolio
8.3.4.3. Fill / Finish Services Offered
8.3.4.4. Recent Developments and Future Outlook
 
8.3.5 PiSA Farmaceutica
8.3.5.1. Company Snapshot
8.3.5.2. Service Portfolio
8.3.5.3. Fill / Finish Services Offered
8.3.5.4. Recent Developments and Future Outlook
 
8.4 Companies Offering Aseptic Fill / Finish Services for Biologics and Small Molecules
8.4.1 Fresenius Kabi
8.4.1.1. Company Snapshot
8.4.1.2 Financial Information
8.4.1.3. Service Portfolio
8.4.1.4. Fill / Finish Services Offered
8.4.1.5. Recent Developments and Future Outlook
 
8.4.2 Recipharm
8.4.2.1. Company Snapshot
8.4.2.2. Financial Information
8.4.2.3. Service Portfolio
8.4.2.4. Fill / Finish Services Offered
8.4.2.5. Recent Developments and Future Outlook
 
9. COMPANY PROFILES: ASEPTIC FILL / FINISH SERVICE PROVIDERS IN ASIA-PACIFIC
9.1 Company Overview
9.2 Companies Offering Aseptic Fill / Finish Services for Biologics
9.2.1 Asymchem
9.2.1.1. Company Snapshot 
9.2.1.2. Financial Information
9.2.1.3. Service Portfolio 
9.2.1.4.  Fill / Finish Services Offered 
9.2.1.5.  Recent Developments and Future Outlook
 
9.2.2. Samsung Biologics
9.2.2.1. Company Snapshot 
9.2.2.2. Financial Information
9.2.2.3.  Service Portfolio 
9.2.2.4.  Fill / Finish Services Offered 
9.2.2.5. Recent Developments and Future Outlook
 
9.2.3.  Syngene
9.2.3.1. Company Snapshot 
9.2.3.2. Financial Information
9.2.3.3.  Service Portfolio 
9.2.3.4.  Fill / Finish Services Offered 
9.2.3.5. Recent Developments and Future Outlook
 
9.2.4. Takara Bio
9.2.4.1. Company Snapshot 
9.2.4.2. Financial Information
9.2.4.3.  Service Portfolio 
9.2.4.4.  Fill / Finish Services Offered 
9.2.4.5. Recent Developments and Future Outlook
 
9.2.5. WuXi Biologics
9.2.5.1. Company Snapshot 
9.2.5.2. Financial Information
9.2.5.3. Service Portfolio 
9.2.5.4.  Fill / Finish Services Offered 
9.2.5.5. Recent Developments and Future Outlook
 
9.2.6. Hetero Drugs
9.2.6.1. Company Snapshot 
9.2.6.2. Fill / Finish Services Offered
9.2.6.3.  Recent Developments and Future Outlook
 
9.2.7. Intas Pharmaceuticals
9.2.7.1. Company Snapshot 
9.2.7.2. Fill / Finish Services Offered
9.2.7.3.  Recent Developments and Future Outlook
 
9.3. Companies Offering Aseptic Fill / Finish Services for Small Molecules
9.3.1. Siegfried
9.3.1.1. Company Snapshot
9.3.1.2. Financial Information
9.3.1.3. Service Portfolio
9.3.1.4. Fill / Finish Services Offered
9.3.1.5. Recent Developments and Future Outlook
 
9.3.2. Wockhardt
9.3.2.1. Company Snapshot
9.3.2.2. Financial Information
9.3.2.3. Service Portfolio
9.3.2.4. Fill / Finish Services Offered
9.3.2.5. Recent Developments and Future Outlook
 
10. PARTNERSHIPS AND COLLABORATIONS 
10.1. Chapter Overview
10.2. Partnership Models
10.3. Aseptic Fill / Finish Service Providers: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership 
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Scale of Operation 
10.3.4. Analysis by Type of Molecule(s) Involved
10.3.5. Analysis by Type of Service(s) Offered
10.3.6. Analysis by Type of Process(es) Involved
10.3.7. Analysis by Type of Drug Product(s) Involved
10.3.8. Most Active Players: Analysis by Number of Partnerships
 
10.3.9. Analysis by Geography 
10.3.9.1. Intercontinental and Intracontinental Agreements
 
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1.  Chapter Overview
11.2.  Forecast Methodology
11.3.  Overall Aseptic Fill / Finish Services Market, 2023-2035 
11.3.1.  Aseptic Fill / Finish Services Market: Analysis by Type of Molecule, 2023-2035
11.3.2.  Aseptic Fill / Finish Services Market: Analysis by Type of Packaging Container Offered, 2023-2035
11.3.3. Aseptic Fill / Finish Services Market: Analysis by Type of Drug Product, 2023-2035
11.3.4. Aseptic Fill / Finish Services Market: Analysis by Target Therapeutic Area, 2023-2035
11.3.5.  Aseptic Fill / Finish Services Market: Analysis by Scale of Operation, 2023-2035
11.3.6.  Aseptic Fill / Finish Services Market: Analysis by Company Size, 2023-2035
11.3.7. Aseptic Fill / Finish Services Market: Analysis by Geography, 2023-2035
 
11.4. Aseptic Fill / Finish Services Market for Biologics, 2023-2035
11.4.1. Aseptic Fill / Finish Services Market for Biologics: Analysis by Type of Packaging Container Offered, 2023-2035
11.4.2. Aseptic Fill / Finish Services Market: Analysis by Type of Drug Product, 2023-2035
11.4.3. Aseptic Fill / Finish Services Market for Biologics: Analysis by Target Therapeutic Area, 2023-2035
11.4.4. Aseptic Fill / Finish Services Market for Biologics: Analysis by Scale of Operation, 2023-2035
11.4.5. Aseptic Fill / Finish Services Market for Biologics: Analysis by Company Size, 2023-2035
11.4.6. Aseptic Fill / Finish Services Market for Biologics: Analysis by Geography, 2023-2035
 
11.5. Aseptic Fill / Finish Services Market for Small Molecules, 2023-2035
11.5.1. Aseptic Fill / Finish Services Market for Small Molecules: Analysis by Type of Packaging Container Offered, 2023-2035
11.5.2. Aseptic Fill / Finish Services Market for Small Molecules: Analysis by Scale of Operation, 2023-2035
11.5.3. Aseptic Fill / Finish Services Market for Small Molecules: Analysis by Company Size, 2023-2035
11.5.4. Aseptic Fill / Finish Services Market for Small Molecules: Analysis by Geography, 2023-2035
 
12. CASE STUDY: ROBOTICS IN PHARMACEUTICAL PACKAGING
12.1.  Chapter Overview
12.2. Role of Robotic Systems in Pharmaceutical Industry
12.3. Role of Robotic Systems in Fill / Finish Operation
12.3.1. Types of Robots Used in Pharmaceutical Operations
12.3.2. Advantages Associated with Robotic Systems
12.3.3. Disadvantages Associated with Robotic Systems
12.4.2. Key Considerations for Selecting a Robotic System
 
12.3. Contract Service Providers: List of Fill / Finish Equipment
12.5. Companies Providing Robots for Use in the Pharmaceutical Industry
12.6. Companies Providing Isolator based Aseptic Filling Systems 
 
12.7. Concluding Remarks
 
13. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS FOR ASEPTIC FILL / FINISH 
13.1. Chapter Overview
13.2. Role of Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations
13.2.1. Advantages of Ready-to-Use Packaging Components
13.2.2. Disadvantages of Ready-to-Use Packaging Components
13.3. Companies Providing Ready-to-Use Packaging Components
13.4. Concluding Remarks
 
14. CONCLUDING REMARKS
 
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. IDT Biologika
15.2.1. Company Snapshot
15.2.1. Interview Transcript: Gregor Kawaletz, Former Chief Commercial Officer
 
15.3. Cytovance Biologics
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Matt Delaney, Former Vice President of Business Development and Marketing
 
15.4. Syngene
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Purushottam Singnurkar, Vice President and Head of Formulation Development
 
15.5. oncomed manufacturing
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Ales Sima, Head of Business Development 
 
15.6. Yposkesi
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Amit, Former Technology Watch Manager
 
15.7. HALIX
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Jos Vergeest, International Business Developer
 
16. APPENDIX 1: TABULATED DATA
 
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1  Executive Summary: Market Landscape of Biologics Fill / Finish Service Providers
Figure 2.2  Executive Summary: Market Landscape of Small Molecules Fill / Finish Service Providers
Figure 2.3  Executive Summary: Partnerships and Collaborations
Figure 2.4  Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Types of Third-Party Service Providers 
Figure 3.2 Commonly Outsourced Fill / Finish Operations 
Figure 3.3 Steps Involved in Aseptic Fill / Finish Process 
Figure 3.4 Blow-Fill-Seal Process
Figure 3.5 Key Considerations for Selecting a CMO Partner
Figure 3.6 Risks and Challenges Associated with Outsourcing Aseptic Fill / Finish Operations
Figure 4.1 Aseptic Fill / Finish Service Providers: Distribution by Year of Establishment
Figure 4.2 Aseptic Fill / Finish Service Providers: Distribution by Company Size
Figure 4.3 Aseptic Fill / Finish Service Providers: Distribution by Location of Headquarters
Figure 4.4 Aseptic Fill / Finish Service Providers: Distribution by Type of Molecule(s)
Figure 4.5 Aseptic Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 5.1 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
Figure 5.2 Biologics Fill / Finish Service Providers: Distribution by Company Size
Figure 5.3 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
Figure 5.4 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Figure 5.5 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 5.6 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered and Type of Drug Product(s) Involved
Figure 5.7 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
Figure 5.8 Biologics Fill / Finish Service Providers: Distribution by Additional Drug Product-related Services Offered
Figure 6.1 Small Molecules Fill / Finish Service Providers: Distribution by Year of Establishment
Figure 6.2 Small Molecules Fill / Finish Service Providers: Distribution by Company Size
Figure 6.3 Small Molecules Fill / Finish Service Providers: Distribution by Location of Headquarters 
Figure 6.4 Small Molecules Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Figure 6.5 Small Molecules Fill / Finish Service Providers: Distribution by Type of Filling Service(s) Offered
Figure 6.6 Small Molecules Fill / Finish Service Providers: Distribution by Type of Finishing Service(s) Offered
Figure 6.7 Small Molecules Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 6.8 Small Molecules Fill / Finish Service Providers: Distribution by Scale of Operation
Figure 6.9 Small Molecules Fill / Finish Service Providers: Distribution by Type of Dosage Form(s) Filled
Figure 6.10 Small Molecules Fill / Finish Service Providers: Distribution by Type of Process(es)
Figure 7.1 AbbVie: Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.2 Baxter (a parent company of BioPharma Solutions): Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.3 Merck (a parent company of BioReliance): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 7.4  Catalent Biologics: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Figure 7.5 Charles River Laboratories: Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.6 Thermo Fisher Scientific (a parent company of Patheon): Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.7 Pfizer CentreOne: Annual Revenues, 2017-9M 2022 (USD Million)
Figure 8.1  Boehringer Ingelheim (a parent company of Boehringer Ingelheim BioXcellence): Annual Revenues, 2017-H1 2022 (EUR Billion) 
Figure 8.2  GlaxoSmithKline: Annual Revenues, 2017 –H1 2022 (GBP Billion)
Figure 8.3  Lonza: Annual Revenues, 2017-H1 2022 (CHF Billion)
Figure 8.4 Pierre Fabre: Annual Revenues, 2018- 2021 (EUR Billion)
Figure 8.5 Wacker Chemie ( a parent company of Wacker Biotech): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 8.6 Aenova: Annual Revenues, 2018-2021 (EUR Million)
Figure 8.7 Fresenius Kabi: Annual Revenues, 2017-9M 2022 (EUR Billion)
Figure 8.8 Recipharm: Annual Revenues, 2017- 2020 (SEK Billion)
Figure 8.9 Recipharm: Revenues by Business Divisions, 2020 (SEK Billion)
Figure 9.1 Asymchem: Annual Revenues, 2017-2020 (USD Billion)
Figure 9.2 Samsung Biologics: Annual Revenues, 2017-H1 2022 (KRW Billion)
Figure 9.3 Syngene: Annual Revenues, FY 2017-FY 2022 (INR Million)
Figure 9.4 Takara Bio: Annual Revenues, FY 2017-FY 2022 (JPY Billion)
Figure 9.5  WuXi Biologics: Annual Revenues, 2017-H1 2022 (RMB Million)
Figure 9.6  Siegfried: Annual Revenues, 2017-H1 2022 (CHF Million)
Figure 9.7 Wockhardt: Annual Revenues, FY 2017- FY Q1 2023 (INR Billion)
Figure 10.1 Partnerships and Collaborations: Cumulative Year wise Trend, 2013-2022   
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Molecule(s) Involved
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Service(s) Offered
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Process(es) Involved
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Drug Product(s) Involved    
Figure 10.8 Most Active Players: Distribution by Number of Partnerships
Figure 10.9 Partnerships and Collaborations: Distribution by Geography
Figure 10.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.1 Global Aseptic Fill / Finish Services Market, 2023-2035 (USD Billion)
Figure 11.2 Aseptic Fill / Finish Services Market: Distribution by Type of Molecule, 2023-2035 (USD Billion)
Figure 11.3 Aseptic Fill / Finish Services Market: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.4 Aseptic Fill / Finish Services Market: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Figure 11.5 Aseptic Fill / Finish Services Market: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Figure 11.6 Aseptic Fill / Finish Services Market: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.7 Aseptic Fill / Finish Services Market: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.8 Aseptic Fill / Finish Services Market: Distribution by Geography, 2023-2035 (USD Billion)
Figure 11.9 Aseptic Fill / Finish Services Market for Biologics, 2023-2035 (USD Billion)
Figure 11.10 Aseptic Fill / Finish Services Market for Biologics: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.11 Aseptic Fill / Finish Services Market for Biologics: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Figure 11.12 Aseptic Fill / Finish Services Market for Biologics: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Figure 11.13 Aseptic Fill / Finish Services Market for Biologics: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.14 Aseptic Fill / Finish Services Market for Biologics: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.15 Aseptic Fill / Finish Services Market for Biologics: Distribution by Geography, 2023-2035 (USD Billion)
Figure 11.16 Aseptic Fill / Finish Services Market for Small Molecules, 2023-2035 (USD Billion)
Figure 11.17 Aseptic Fill / Finish Services Market for Small Molecules: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.18 Aseptic Fill / Finish Services Market for Small Molecules: Distribution by Scale of Operation, 2023-2035 (USD Billion) 
Figure 11.19 Aseptic Fill / Finish Services Market for Small Molecules: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.20 Aseptic Fill / Finish Services Market for Small Molecules: Distribution by Geography, 2023-2035 (USD Billion)
Figure 12.1 Key Considerations for Selecting a Robotic System
Figure 12.2 Advantages of Robotic Systems in Pharmaceutical Operations
Figure 13.1 Key Drivers of Ready-to-Use Platform
Figure 14.1 Concluding Remarks: Current Biologic Fill / Finish Service Providers Market Landscape 
Figure 14.2 Concluding Remarks: Current Small Molecule Fill / Finish Service Providers Market Landscape 
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Market Sizing and Opportunity Analysis
 

List Of Tables

Table 4.1 Aseptic Fill / Finish Service Providers: List of Companies
Table 4.2 Aseptic Fill / Finish Service Providers: Information on Type of Packaging Container(s) Offered 
Table 5.1 Biologics Fill / Finish Service Providers: List of Companies
Table 5.2 Biologics Fill / Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 5.3 Biologics Fill / Finish Service Providers: Information on Type of Drug Product(s) Involved
Table 5.4 Biologics Fill / Finish Service Providers: Information on Scale of Operation
Table 5.5 Biologics Fill / Finish Service Providers: Information on Additional Drug Product-related Services Offered
Table 5.6 Biologics Fill / Finish Service Providers: Information on Fill / Finish Capacity
Table 6.1 Small Molecules Fill / Finish Service Providers: List of Companies
Table 6.2 Small Molecules Fill / Finish Service Providers: Information on Fill / Finish Technique
Table 6.3 Small Molecules Fill / Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 6.4 Small Molecules Fill / Finish Service Providers: Information on Scale of Operation
Table 6.5 Small Molecules Fill / Finish Service Providers: Information on Type of Dosage Form(s) Filled and Type of Process(es)
Table 6.6 Small Molecules Fill / Finish Service Providers: Information on Fill / Finish Capacity
Table 7.1 Biologics Fill / Finish Service Providers: List of Companies Profiled
Table 7.2 AbbVie Contract Manufacturing: Company Snapshot
Table 7.3 AbbVie Contract Manufacturing: Service Portfolio
Table 7.4  AbbVie Contract Manufacturing: Fill / Finish Services
Table 7.5 AbbVie Contract Manufacturing: Sterile Manufacturing Facilities
Table 7.6 AbbVie Contract Manufacturing: Recent Developments and Future Outlook
Table 7.7 BioPharma Solutions: Company Snapshot
Table 7.8 BioPharma Solutions: Service Portfolio 
Table 7.9  BioPharma Solutions: Fill / Finish Services
Table 7.10 BioPharma Solutions: Sterile Manufacturing Facilities
Table 7.11 BioPharma Solutions: Recent Developments and Future Outlook
Table 7.12 BioReliance: Company Snapshot
Table 7.13 BioReliance: Service Portfolio 
Table 7.14 BioReliance: Fill / Finish Services
Table 7.15 BioReliance: Sterile Manufacturing Facilities
Table 7.16 BioReliance: Recent Developments and Future Outlook
Table 7.17 Catalent Biologics: Company Snapshot
Table 7.18 Catalent Biologics: Service Portfolio 
Table 7.19  Catalent Biologics: Fill / Finish Services
Table 7.20 Catalent Biologics: Sterile Manufacturing Facilities
Table 7.21 Catalent Biologics: Recent Developments and Future Outlook
Table 7.22 Charles River Laboratories: Company Snapshot
Table 7.23 Charles River Laboratories: Fill / Finish Services
Table 7.24  Charles River Laboratories: Sterile Manufacturing Facilities
Table 7.25 Charles River Laboratories: Recent Developments and Future Outlook
Table 7.26 Patheon: Company Snapshot
Table 7.27 Patheon: Service Portfolio
Table 7.28 Patheon: Fill / Finish Services
Table 7.29 Patheon: Recent Developments and Future Outlook
Table 7.30 Small Molecules Fill / Finish Service Providers: List of Companies Profiled
Table 7.31 Pfizer CentreOne: Company Snapshot
Table 7.32 Pfizer CentreOne: Service Portfolio
Table 7.33 Pfizer CentreOne: Fill / Finish Services
Table 7.34 Pfizer CentreOne: Recent Developments and Future Outlook
Table 7.35 Plastikon Healthcare: Company Snapshot
Table 7.36 Plastikon Healthcare: Service Portfolio 
Table 7.37 Plastikon Healthcare: Fill / Finish Services
Table 7.38 Sharp Services: Company Snapshot
Table 7.39 Sharp Services: Service Portfolio
Table 7.40 Sharp Services: Fill / Finish Services
Table 7.41 Sharp Services: Recent Developments and Future Outlook
Table 8.1 Biologics Fill / Finish Service Providers in Europe: List of Companies Profiled
Table 8.2 Boehringer Ingelheim BioXcellence: Company Snapshot
Table 8.3 Boehringer Ingelheim BioXcellence: Service Portfolio 
Table 8.4 Boehringer Ingelheim BioXcellence: Fill / Finish Services
Table 8.5 Boehringer Ingelheim BioXcellence: Sterile Manufacturing Facilities
Table 8.6 Boehringer Ingelheim BioXcellence: Recent Developments and Future Outlook
Table 8.7 Fareva: Company Snapshot
Table 8.8 Fareva: Fill / Finish Services
Table 8.9 Fareva: Recent Developments and Future Outlook
Table 8.10 Glaxo SmithKline: Company Snapshot
Table 8.11 Glaxo SmithKline: Fill / Finish Services
Table 8.12 Glaxo SmithKline: Recent Developments and Future Outlook
Table 8.13 Lonza: Company Snapshot
Table 8.14 Lonza: Service Portfolio
Table 8.15 Lonza: Fill / Finish Services 
Table 8.16 Lonza: Recent Developments and Future Outlook
Table 8.17 Pierre Fabre: Company Snapshot
Table 8.18 Pierre Fabre: Service Portfolio 
Table 8.19  Pierre Fabre: Fill / Finish Services
Table 8.20 Pierre Fabre: Sterile Manufacturing Facilities
Table 8.21 Pierre Fabre: Recent Developments and Future Outlook
Table 8.22 Wacker Biotech: Company Snapshot
Table 8.23 Wacker Biotech: Service Portfolio
Table 8.24  Wacker Biotech: Fill / Finish Services
Table 8.25 Wacker Biotech: Sterile Manufacturing Facilities
Table 8.26 Wacker Biotech: Recent Developments and Future Outlook
Table 8.27 Small Molecules Fill / Finish Service Providers in Europe: List of Companies Profiled
Table 8.28 Aenova: Company Snapshot
Table 8.29 Aenova: Service Portfolio  
Table 8.30 Aenova: Fill / Finish Services
Table 8.31 Aenova: Recent Developments and Future Outlook
Table 8.32 APL: Company Snapshot
Table 8.33 APL: Service Portfolio
Table 8.34  APL: Fill / Finish Services
Table 8.35 CordenPharma: Company Snapshot
Table 8.36 CordenPharma: Service Portfolio
Table 8.37 CordenPharma: Fill / Finish Services
Table 8.38 CordenPharma: Recent Developments and Future Outlook
Table 8.39  Delpharm: Company Snapshot
Table 8.40 Delpharm: Service Portfolio
Table 8.41 Delpharm: Fill / Finish Services
Table 8.42 Delpharm: Recent Developments and Future Outlook
Table 8.43 PiSA Farmaceutica: Company Snapshot
Table 8.44 PiSA Farmaceutica: Fill / Finish Services
Table 8.45 Biologics and Small Molecules Fill / Finish Service Providers in Europe: List of Companies Profiled
Table 8.46 Fresenius Kabi: Company Snapshot
Table 8.47 Fresenius Kabi: Fill / Finish Services
Table 8.48 Recipharm: Company Snapshot
Table 8.49 Recipharm: Service Portfolio
Table 8.50 Recipharm: Fill / Finish Services
Table 8.51 Recipharm: Recent Developments and Future Outlook
Table 9.1 Biologics Fill / Finish Service Providers in Asia-Pacific: List of Companies Profiled
Table 9.2 Asymchem: Company Snapshot
Table 9.3 Asymchem: Service Portfolio 
Table 9.4  Asymchem: Fill / Finish Services
Table 9.5 Asymchem: Sterile Manufacturing Facilities
Table 9.6 Asymchem: Recent Developments and Future Outlook
Table 9.7  Samsung Biologics: Company Snapshot
Table 9.8  Samsung Biologics: Service Portfolio
Table 9.9 Samsung Biologics: Fill / Finish Services
Table 9.10  Samsung Biologics: Recent Developments and Future Outlook
Table 9.11 Syngene: Company Snapshot
Table 9.12 Syngene: Service Portfolio 
Table 9.13  Syngene: Fill / Finish Services
Table 9.14 Syngene: Recent Developments and Future Outlook
Table 9.15 Takara Bio: Company Snapshot
Table 9.16 Takara Bio: Service Portfolio 
Table 9.17  Takara Bio: Fill / Finish Services
Table 9.18 Takara Bio: Recent Developments and Future Outlook
Table 9.19 WuXi Biologics: Company Snapshot
Table 9.20 WuXi Biologics: Services Portfolio
Table 9.21  Wuxi Biologics: Fill / Finish Services
Table 9.22 WuXi Biologics: Sterile Manufacturing Facilities
Table 9.23 WuXi Biologics: Recent Developments and Future Outlook
Table 9.24  Hetero Drugs: Company Snapshot
Table 9.25  Hetero Drugs: Fill / Finish Services
Table 9.26  Intas Pharmaceuticals: Company Snapshot
Table 9.27  Intas Pharmaceuticals: Fill / Finish Services
Table 9.28 Small Molecules Fill / Finish Service Providers in Asia-Pacific: List of Companies Profiled
Table 9.29 Siegfried: Company Snapshot
Table 9.30  Siegfried: Service Portfolio
Table 9.31 Siegfried: Fill / Finish Services
Table 9.32 Siegfried: Recent Developments and Future Outlook
Table 9.33 Wockhardt: Company Snapshot
Table 9.34  Wockhardt: Fill / Finish Services
Table 9.35 Wockhardt: Recent Developments and Future Outlook
Table 10.1 Aseptic Fill / Finish Service Providers: Partnerships and Collaborations  
Table 10.2 Partnerships and Collaborations: Information on Type of Molecule(s) Involved and Type of Service(s) Offered 
Table 10.3 Partnerships and Collaborations: Information on Type of Drug Product(s) Involved  and Type of Process(es) Involved
Table 12.1 Contract Service Providers: Information on Fill / Finish Equipment   
Table 12.2 List of Pharmaceutical Robotics Manufacturers
Table 12.3 Isolator based Aseptic Filling Systems: Information on Compatible Primary Container
Table 13.1 List of Companies Supplying Ready-to-Use Aseptic Packaging Components
Table 16.1 Aseptic Fill / Finish Service Providers: Distribution by Year of Establishment
Table 16.2 Aseptic Fill / Finish Service Providers: Distribution by Company Size
Table 16.3 Aseptic Fill / Finish Service Providers: Distribution by Location of Headquarters
Table 16.4 Aseptic Fill / Finish Service Providers: Distribution by Type of Molecule(s)
Table 16.5 Aseptic Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.6 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
Table 16.7 Biologics Fill / Finish Service Providers: Distribution by Company Size
Table 16.8 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
Table 16.9 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Table 16.10 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.11 Biologics Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered and Type of Drug Product(s) Involved
Table 16.12 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
Table 16.13 Biologics Fill / Finish Service Providers: Distribution by Additional Drug Product-related Services Offered
Table 16.14 Small Molecules Fill / Finish Service Providers: Distribution by Year of Establishment
Table 16.15 Small Molecules Fill / Finish Service Providers: Distribution by Company Size
Table 16.16 Small Molecules Fill / Finish Service Providers: Distribution by Location of Headquarters 
Table 16.17 Small Molecules Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Table 16.18 Small Molecules Fill / Finish Service Providers: Distribution by Type of Filling Service(s) Offered
Table 16.19 Small Molecules Fill / Finish Service Providers: Distribution by Type of Finishing Service(s) Offered
Table 16.19 Small Molecules Fill / Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.20 Small Molecules Fill / Finish Service Providers: Distribution by Scale of Operation
Table 16.21 Small Molecules Fill / Finish Service Providers: Distribution by Type of Dosage Form(s) Filled
Table 16.22 Small Molecules Fill / Finish Service Providers: Distribution by Type of Process(es)
Table 16.23 AbbVie: Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.24 Baxter (a parent company of BioPharma Solutions): Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.25 Merck (a parent company of BioReliance): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.26 Catalent Biologics: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Table 16.27 Charles River Laboratories: Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.28 Thermo Fisher Scientific (a parent company of Patheon): Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.29 Pfizer CentreOne: Annual Revenues, 2017-9M 2022 (USD Million)
Table 16.30 Boehringer Ingelheim (a parent company of Boehringer Ingelheim BioXcellence): Annual Revenues, 2017-H1 2022 (EUR Billion) 
Table 16.31 GlaxoSmithKline: Annual Revenues, 2017 –H1 2022 (GBP Billion)
Table 16.32 Lonza: Annual Revenues, 2017-H1 2022 (CHF Billion)
Table 16.33 Pierre Fabre: Annual Revenues, 2018- 2021 (EUR Billion)
Table 16.34 Wacker Chemie ( a parent company of Wacker Biotech): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.35 Aenova: Annual Revenues, 2018-2021 (EUR Million)
Table 16.36 Fresenius Kabi: Annual Revenues, 2017-9M 2022 (EUR Billion)
Table 16.37 Recipharm: Annual Revenues, 2017- 2020 (SEK Billion)
Table 16.38 Recipharm: Revenues by Business Divisions, 2020 (SEK Billion)
Table 16.39 Asymchem: Annual Revenues, 2017-2020 (USD Billion)
Table 16.40 Samsung Biologics: Annual Revenues, 2017-H1 2022 (KRW Billion)
Table 16.41 Syngene: Annual Revenues, FY 2017-FY 2022 (INR Million)
Table 16.42 Takara Bio: Annual Revenues, FY 2017-FY 2022 (JPY Billion)
Table 16.43 WuXi Biologics: Annual Revenues, 2017-H1 2022 (RMB Million)
Table 16.44 Siegfried: Annual Revenues, 2017-H1 2022 (CHF Million)
Table 16.45 Wockhardt: Annual Revenues, FY 2017- FY Q1 2023 (INR Billion)
Table 16.46 Partnerships and Collaborations: Cumulative Year wise Trend, 2013-2022   
Table 16.47 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.48 Partnerships and Collaborations: Distribution by Scale of Operation
Table 16.49 Partnerships and Collaborations: Distribution by Type of Molecule(s) Involved
Table 16.50 Partnerships and Collaborations: Distribution by Type of Service(s) Offered
Table 16.51 Partnerships and Collaborations: Distribution by Type of Process(es) Involved
Table 16.52 Partnerships and Collaborations: Distribution by Type of Drug Product(s) Involved    
Table 16.53 Most Active Players: Distribution by Number of Partnerships
Table 16.54 Partnerships and Collaborations: Distribution by Geography
Table 16.55 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.56 Global Aseptic Fill / Finish Services Market, 2023-2035 (USD Billion)
Table 16.57 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Molecule, 2023-2035 (USD Billion)
Table 16.58 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.59 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Table 16.60 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Table 16.61 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.62 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.63 Aseptic Fill / Finish Services Market, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)
Table 16.64 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 16.65 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.66 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Table 16.67 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Table 16.68 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.69 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.70 Aseptic Fill / Finish Services Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)
Table 16.71 Aseptic Fill / Finish Services Market for Small Molecules, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 16.72 Aseptic Fill / Finish Services Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.73 Aseptic Fill / Finish Services Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion) 
Table 16.74 Aseptic Fill / Finish Services Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.75 Aseptic Fill / Finish Services Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 3P Biopharmaceuticals
  2. Aalto Scientific
  3. ABB
  4. AbbVie
  5. AbbVie Contract Manufacturing
  6. AbTis
  7. Abzena
  8. ACG
  9. ACIC Pharmaceutical Machinery
  10. AdaptVac
  11. ADC Biotechnology
  12. Adimmune 
  13. Advanced BioScience Laboratories
  14. Aenova
  15. Affinity Life Sciences
  16. Afton Scientific
  17. Agilis Biotherapeutics
  18. AJ Biologics
  19. Ajinomoto Bio-Pharma
  20. Akorn
  21. Akron Biotech
  22. Akso Biopharmaceutical
  23. Akums Drugs & Pharmaceuticals
  24. Alanza
  25. Alcami (Acquired by GHO Capital and The Vistria Group)
  26. Alcon
  27. Aldevron
  28. Alkermes
  29. Allergy Laboratories
  30. Althea
  31. Amatsigroup
  32. Ambica Pharma Machines
  33. Amgen
  34. Amicus Therapeutics 
  35. Amsino International
  36. Anchiano Therapeutics (formerly known as BioCanCell)
  37. Anchor Mark
  38. Anthos Therapeutics
  39. apceth Biopharma
  40. APG Europe
  41. ApiJect Systems
  42. APL
  43. Aptar Pharma
  44. Aptuit
  45. Arabio
  46. ARaymond Life
  47. Arch Biopartners
  48. Argonaut Manufacturing Services
  49. ARISTO Pharmaceuticals
  50. Ascendia Pharmaceuticals
  51. Asept Pak
  52. Aseptic Technologies
  53. Asklepios BioPharmaceutical
  54. AST
  55. AstraZeneca
  56. Asymchem
  57. Ausia Biotech
  58. Austrianova
  59. Automated Systems of Tacoma
  60. Avara Pharmaceutical Services
  61. Avid Bioservices
  62. Avrio Biopharmaceuticals
  63. AWS Bio-Pharma Technologies
  64. Axcellerate Pharma
  65. B. Braun’s OEM Division
  66. Baccinex
  67. Basic Pharma
  68. Bausch & Ströbel
  69. BAUSCH Advanced Technology (BATG)
  70. Baxter BioPharma Solutions
  71. Bayer
  72. BD
  73. BePharBel Manufacturing
  74. Berkshire Sterile Manufacturing
  75. Binex
  76. Bio Elpida
  77. Bio-Concept Laboratories
  78. BioConnection
  79. Biofabri 
  80. Biogen
  81. BioMARC
  82. Biomay
  83. Biomedical Advanced Research and Development Authority (BARDA)
  84. BioNTech 
  85. BioPharma Solutions
  86. BioReliance
  87. Bio-Serv
  88. BioSkryb Genomics
  89. BioTechLogic
  90. BioTechnique
  91. Biovian
  92. BirgiMefar
  93. Boehringer Ingelheim BioXcellence
  94. Bolt Biotherapeutics
  95. Bosch Packaging Technology
  96. Boston Children’s Hospital
  97. Bristol-Myers Squibb
  98. Bryllan
  99. BSP Pharmaceuticals
  100. Burrard Pharmaceuticals
  101. Bushu Pharmaceuticals
  102. Cangene Corporation (Acquired by Emergent BioSolutions)
  103. Canton Biologics
  104. Capmatic
  105. CARBOGEN AMCIS
  106. Carlyle 
  107. Catalent Biologics
  108. Catalent Pharma Solutions
  109. Celgene
  110. Cell Culture Company 
  111. Cellin Technologies
  112. Celonic
  113. Celsee
  114. Cenexi
  115. Cerbios-Pharma
  116. Cerium Pharmaceuticals
  117. Chase-Logeman
  118. Chemigran 
  119. ChemPartner
  120. Chime Biologics
  121. China Gateway Biologics
  122. CinnaGen
  123. Cirondrugs
  124. Citryll
  125. CMAB Biopharma
  126. CMC Biologics
  127. CMIC CMO
  128. Coalition for the Promotion of Innovations for Epidemic Preparedness (CEPI)
  129. Cobra Biologics
  130. C.O.C. Farmaceutici 
  131. Cognate BioServices
  132. Cognitus Consulting
  133. Coldstream Laboratories
  134. Colorado State University
  135. Columbus Venture Partners
  136. Comecer
  137. Concord Drugs
  138. Cook Pharmica
  139. CordenPharma
  140. Cozzoli Machine Company
  141. Creative Biolabs
  142. CreoSalus
  143. Crystal Pharma
  144. CureVac
  145. Curida
  146. CytoDyn
  147. Cytovance Biologics
  148. Daikyo Seiko
  149. Dalton Pharma Services
  150. Dara Pharma
  151. Datwyler Sealing Solutions
  152. Delpharm 
  153. DENSO 
  154. Dhruv Life Sciences
  155. Disposable Lab
  156. DM Bio
  157. Drugs for Neglected Disease Initiative (DNDi)
  158. DSM Pharmaceutical Products
  159. DWK Life Sciences
  160. EirGen Pharma
  161. EirGenix
  162. Eli Lilly
  163. EMA Pharmaceuticals
  164. EMCM
  165. Emcure Pharmaceuticals
  166. Emergent BioSolutions
  167. Esco Aster
  168. Etinpro
  169. EuBiologics
  170. EUCODIS Bioscience
  171. Eurofins
  172. Eurofins BioPharma Product Testing Netherlands (EBPT NL)
  173. Euro-Med Laboratories
  174. EVER Pharma
  175. Evonik Health Care
  176. ExCellThera
  177. Exelead
  178. Experic
  179. Extract Technology
  180. FANUC America
  181. Fareva
  182. FinVector 
  183. Flamingo Pharmaceuticals
  184. Formosa Laboratories
  185. Fresenius Kabi Contract Manufacturing
  186. Früh Verpackungstechnik
  187. FUJIFILM Diosynth Biotechnologies
  188. GC Pharma
  189. GEA
  190. Gebro Pharma
  191. Genentech
  192. GeneQuantum Healthcare
  193. Generic Specialities
  194. GenIbet Biopharmaceuticals
  195. Genovior Biotech 
  196. Genprex
  197. Gerresheimer
  198. Getinge
  199. GigaGen
  200. Gilead
  201. Gland Pharma
  202. GLyPharma 
  203. Goodwin Biotechnology
  204. GP Pharm
  205. Grand River Aseptic Manufacturing
  206. groninger
  207. GSK
  208. GTCR
  209. Gulf Biotech
  210. HALIX
  211. hameln pharma
  212. Handl Therapeutics
  213. Hanford Pharmaceuticals
  214. Hansa Biopharma
  215. Hapten Sciences
  216. Health Biotech
  217. Healthcare Pharmaceuticals
  218. Healthy Life Pharma
  219. Hepalink
  220. Hetero Drugs
  221. Hisun Pharmaceuticals USA
  222. HOOKIPA Pharma
  223. Horizon Therapeutics
  224. Hospira (Acquired by Pfizer)
  225. Humanigen
  226. Hybio Pharmaceutical
  227. Hycult Biotech
  228. iBio
  229. IDT Australia
  230. IDT Biologika
  231. IMA Group
  232. Immune Pharmaceuticals
  233. Immunex
  234. INCOG BioPharma Services
  235. Indicia
  236. Industria Macchine Automatiche (IMA)
  237. Infectious Disease Research Institute
  238. Injectalia (A subsidiary of Orofino Pharmaceuticals)
  239. Intas Pharmaceuticals
  240. Integrity Bio
  241. Irvine Pharmaceutical Services
  242. Istituto Biochimico Italiano Giovanni Lorenzini 
  243. Janssen Pharmaceuticals
  244. JHL Biotech
  245. Jiangsu Yaohai Bio-pharmaceutical
  246. Johnson & Johnson
  247. JOINN Biologics
  248. Jubilant HollisterStier
  249. Kanda BioTech
  250. Kaneka Eurogentec
  251. Kawasaki Heavy Industries
  252. Kaysersberg Pharmaceuticals (Acquired by Recipharm)
  253. Kemwell Biopharma
  254. Klenzaids
  255. Kohlberg and Mubadala
  256. KP Pharmaceutical Technology
  257. KUKA
  258. Kymanox 
  259. Laboratorios Farmaceuticos ROVI
  260. Laekna Therapeutics
  261. LakePharma
  262. LamKap Bio
  263. Lava Therapeutics
  264. Legacy Pharmaceuticals
  265. LESVI
  266. Lifecore Biomedical
  267. Liof Pharma
  268. Lohmann Pharma Herstellung
  269. Lomapharm
  270. Lonza
  271. Lubrizol
  272. LuinaBio
  273. LyoGen
  274. Lyophilization Services of New England (LSNE) (Acquired by PCI Pharma)
  275. Lyophilization Technology
  276. M&O Perry
  277. MabPlex
  278. MabPlex 
  279. Madison Dearborn Partners
  280. Magle Chemoswed
  281. Makcur Laboratories
  282. Marchesini Group
  283. MassBiologics
  284. Massman Automation Designs
  285. MaSTherCell
  286. Masy BioServices
  287. MEDInstill
  288. Merck
  289. Microdermics 
  290. Millmount Healthcare (Acquired by PCI Pharma Services)
  291. Miltenyi Biotec
  292. Minaris Regenerative Medicine
  293. Mithra CDMO
  294. Mitsubishi Electric
  295. Moderna
  296. Morgridge Institute for Research (MIR)
  297. Mycenax Biotech
  298. Najít Technologies
  299. National Health Research Institutes (NHRI)
  300. National Institutes of Health
  301. Navesta
  302. NBE Therapeutics
  303. Nephron Pharmaceuticals
  304. Neuma (Acquired by Kymanox)
  305. New Vision Pharmaceuticals
  306. NextPharma
  307. Nikon CeLL innovation
  308. Ningbo Zhengli Pharmaceutical Packing
  309. Nipro PharmaPackaging
  310. Nitto Avecia
  311. n-Lorem Foundation
  312. Northway Biotech 
  313. Nova Laboratories
  314. Novartis
  315. Novasep
  316. Novavax
  317. Noveome Biotherapeutics
  318. Novex Innovations
  319. Novo Nordisk
  320. Novocol Pharma
  321. Nykode Therapeutics (formerly known as Vaccibody)
  322. Oakwood Labs
  323. Ology Bioservices
  324. OmniChem
  325. OMRON Industrial Automation
  326. oncomed manufacturing
  327. Oncotec Pharma Produktion
  328. OPKO Health
  329. OPTIMA
  330. Ori Biotech
  331. Orion Corporation
  332. Oryn Therapeutics
  333. OSO Biopharmaceuticals Manufacturing (Acquired by AMRI)
  334. Ottawa Hospital Research Institute
  335. Oxford BioMedica
  336. Pace Analytical
  337. PaizaBio
  338. Pall Life Sciences
  339. Panacea Pharmaceuticals
  340. Panpharma
  341. Paragon Bioservices
  342. Particle Measuring Systems (PMS)
  343. Partners Group
  344. Patheon (Acquired by Thermo Fisher Scientific)
  345. PCI Pharma Services
  346. Penn Pharmaceutical Services
  347. Permira
  348. Pfizer
  349. Pfizer CentreOne
  350. Pharma Stulln
  351. Pharmaceutical Packaging Professionals
  352. Pharmaceutics International
  353. Pharma-Q
  354. Pharmaster  
  355. PharmaTher 
  356. Pierre Fabre
  357. Pii (Pharmaceutics International Inc.)
  358. Piramal Pharma Solutions
  359. PiSA Farmacéutica
  360. Plastikon Healthcare
  361. PMI BioPharma Solutions
  362. Polfa Tarchomin
  363. Polpharma Biologics
  364. Polymun Scientific
  365. Praxis Pharmaceutical
  366. PrimaPharma
  367. Prince Sterilization Services
  368. PSC Biotech
  369. PYRAMID Laboratories
  370. Quality BioResources
  371. QureBio
  372. Recipharm
  373. Regeneron Pharmaceuticals
  374. Reliance Life Sciences
  375. Renaissance Lakewood
  376. Rentschler Biopharma
  377. Rentschler Fill Solutions
  378. Resilience
  379. Revance Therapeutics
  380. Roche
  381. Romaco
  382. Rommelag CMO
  383. Rompharm
  384. RoslinCT
  385. ROTA Verpackungstechnik
  386. Ruibo Bio-Technology
  387. Russian Direct Investment Fund (RDIF)
  388. Saint-Gobain
  389. Salvat
  390. Sam Chun Dang Pharm
  391. Samsung Bioepis
  392. Samsung Biologics
  393. Sandoz
  394. Sanofi
  395. Saudi Biotechnology Manufacturing
  396. Schematic Engineering Industries
  397. SCHOTT 
  398. ScinoPharm
  399. Seiko Epson
  400. Selecta Biosciences
  401. Selkirk Pharma
  402. Sensorion
  403. Sentiss Pharma
  404. BravoBio
  405. Sharp 
  406. Shengnuo Peptide
  407. Shenzhen Techdow Pharmaceutical
  408. Sherpa Clinical Packaging (Acquired by PCI Pharma Services)
  409. Shibuya
  410. Shree Bhagwati Machtech 
  411. SialoCarb
  412. Siam Bioscience
  413. Siegfried Holding
  414. Singota Solutions
  415. Sio Gene Therapies
  416. SiO2 Medical Products
  417. SIRION Biotech 
  418. Sirton Pharmaceuticals
  419. SKAN
  420. Snowbell Machines
  421. Societal CDMO
  422. SP Industries
  423. Spanish Agency of Medicines and Medical Devices (AEMPS)
  424. Square Pharmaceuticals
  425. Staubli
  426. Stelis Biopharma
  427. Steriline
  428. Stevanato
  429. Surrozen
  430. Swissfillon
  431. Symbiosis Pharmaceutical
  432. Symphogen
  433. SynCo Bio Partners
  434. Syngene
  435. Synklino
  436. Syntegon
  437. Sypharma
  438. TAIYO Pharma 
  439. Takara Bio
  440. Tanvex BioPharma
  441. Taysha Gene Therapies
  442. Tekpak
  443. ten23 health
  444. Themis Medicare
  445. Therapure Biomanufacturing
  446. Theratechnologies
  447. Thermo Fisher Scientific
  448. Tofflon
  449. Transcoject
  450. TransMedics
  451. TriPharm Services (Acquired by Alcami)
  452. Truking Technology
  453. Tubulis
  454. U.S. Army Contracting Command (ACC)
  455. UCB
  456. Ultragenyx Pharmaceutical
  457. Unicep
  458. Unipharma
  459. Unither Pharmaceuticals
  460. Universal Robots
  461. University of Iowa Pharmaceuticals
  462. University of Queensland
  463. Unolab Manufacturing
  464. USV
  465. Vaccine and Infectious Disease Organization (VIDO)
  466. Vanrx Pharmasystems
  467. Vaxine
  468. VBI Vaccines
  469. Vetter Pharma
  470. VGXI
  471. Vibalogics
  472. Vigene Biosciences
  473. Viralgen
  474. V-nano
  475. VxP Biologics
  476. VxP Pharma
  477. WACKER Biotech
  478. Waisman Biomanufacturing
  479. Watson-Marlow
  480. West Pharmaceutical Services
  481. Wockhardt
  482. WuXi Biologics
  483. Wuxi Fortune Pharmaceutical
  484. Wuxi Griffin
  485. Yaskawa Electric
  486. Yposkesi 
  487. Zoetis

Source 1: https://biologics.catalent.com/expert-content/drug-substance-manufacturing/trends-in-biologics-manufacturing-from-drug-substance-to-fill-finish/
Source 2: https://www.pharmtech.com/view/fillfinish-outsourcing

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.